Avinger announced it will present the CONNECT II global clinical trial results at the Vascular Interventional Advances (VIVA) Conference 2012 in Las Vegas, USA, (9–12 October 2012).
CONNECT II is a global clinical study that evaluated the safety and efficacy of Ocelot, the first-ever interventional chronic total occlusion (CTO) crossing catheter to incorporate Optical Coherence Tomography, or OCT. This technology is used to get visualisation inside the artery, allowing physicians to navigate, see, and cross totally blocked arteries in the legs of patients suffering from peripheral arterial disease.
Final results will be revealed at a Late Breaking Clinical Trial session on 11 October 2012 by interventional cardiologist, Matt Selmon, CONNECT II co-principal investigator of Heart Hospital, Austin, USA.
